An Open-Label Extension Study to Assess the Long-term Effect of EDG-5506 on Safety, Biomarkers, and Functional Measures in Adults and Adolescents With Becker Muscular Dystrophy.
Latest Information Update: 29 Aug 2024
At a glance
- Drugs Sevasemten (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms MESA
- Sponsors Edgewise Therapeutics
- 27 Sep 2023 Status changed from planning to recruiting.
- 07 Nov 2021 New trial record
- 28 Oct 2021 According to an Edgewise Therapeutics media release, the company plans to initiate this study in the first quarter of 2022.